KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
KAUST Ph.D. student Khalil Moussi won two awards at the IEEE International Conference on Nano/Micro Engineered and Molecular Systems for his research on a miniaturized drug delivery system. The system, developed in collaboration with KAIMRC, uses 3D printing and wireless power to deliver drugs for coronary artery disease treatment. The device features an electrochemical micro-pump, a 3D printed reservoir with microneedles, and a wireless powering unit, allowing customization for various in vivo drug delivery applications. Why it matters: This recognition highlights KAUST's contributions to biomedical engineering and its potential to develop innovative solutions for critical healthcare challenges in the region and beyond.
Scientists at King Abdullah University of Science and Technology (KAUST) have engineered tiny metal-organic frameworks (MOFs) to deliver a team of six proteins into living cells. Inside the cells, these proteins formed a nanoscale factory that successfully produced violacein, a natural bioactive compound with therapeutic potential. This breakthrough represents the most complex multiprotein system delivered into living cells to date and the first example of a 'protein pathway transplant'. Why it matters: This research offers an early demonstration of how future therapies might generate treatment molecules directly inside the body at disease sites, potentially leading to more precise and less toxic medical interventions.
Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
KAUST researchers are exploring novel chemical reactors and separation processes using mathematical design, with a focus on time and shape variables to enhance transport, heat transfer, and mass transfer. By aligning design, modeling, and 3D printing, they create customized shapes with great complexity and less material. This approach allows for the creation of bespoke reactors and separation processes tailored to specific applications, improving efficiency and reducing energy consumption. Why it matters: This research demonstrates the potential of advanced manufacturing techniques to revolutionize industrial design in the Middle East's chemical and pharmaceutical sectors.